ADVERSE REACTIONS TO FIRST-LINE ANTI-TUBERCULOSIS DRUGS AS A RISK FACTOR OF PULMONARY TUBERCULOSIS TREATMENT DEFAULT IN JAKARTA, INDONESIA

STEFANUS IMANUEL SETIAWAN; PURWANTYASTUTI ASCOBAT

doi:10.22159/ijap.2019.v11s6.33551

Authors

STEFANUS IMANUEL SETIAWAN Faculty of Medicine Universitas Indonesia, Jakarta
PURWANTYASTUTI ASCOBAT Department of Pharmacology and Therapeutic, Faculty of Medicine Universitas Indonesia, Jakarta

DOI:

https://doi.org/10.22159/ijap.2019.v11s6.33551

Keywords:

Adverse reaction, Anti-tuberculosis drug, Treatment default, Pulmonary tuberculosis

Abstract

Objective: Tuberculosis (TB) is one of the leading fatal infectious diseases and remains a major health problem worldwide. Moreover, adverse effects of TB treatment can escalate treatment default. This study aimed to evaluate the correlation between adverse reactions to anti-TB drugs and treatment default.

Methods: We performed a cross-sectional study using medical record data of a total 172 adult patients with pulmonary TB who were treated with first-line anti-TB drugs at Dr. Cipto Mangunkusumo National General Hospital in Jakarta, Indonesia during 2014 and who experienced adverse reactions.

Results: Of the total, 127 patients (73.8%) had minor adverse reactions and 45 patients (26.2%) experienced major adverse reactions. Predominant adverse reactions included gastrointestinal disorders (34%) and drug-induced hepatitis (60%). There was a significant correlation between adverse reactions to anti-TB drugs and treatment default cases (odds ratio (OR), 9.33; 95% confidence interval (CI), 4.20–20.72; p<0.001). The results of multivariate analysis showed that TB treatment outcome is affected by adverse drug reactions (OR, 10.91; 95% CI, 4.62–25.75; p<0.001), drug use in treating concomitant diseases (OR, 3.03; 95% CI, 1.30–7.05; p=0.010), and type of anti-TB drug used (OR, 2.41; 95% CI, 0.99–5.83; p=0.045).

Conclusion: Based on these results, we showed that adverse reactions to anti-TB drugs can affect TB treatment outcome and can serve as a risk factor to treatment default.

Downloads

Download data is not yet available.

References

1. World Health Organization. Global tuberculosis report; 2015. Available from: http://www.who.int/tb/publications/global_report/en/ [Last accessed 13 Oct 2016]
2. Rofiq A, Karyana M, Azhar K, Syarif AK, Indah RM. Penyakit menular. In: Badan Litbangkes. Riset kesehatan dasar. Kemenkes RI; 2013. p. 69-71.
3. Isbaniyah F, Thabrani Z, Soepandi PZ, Burhan E, Soedarsono, Reviono R, et al. Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia; 2011. p. 24-47.
4. Mustikawati DE, Surya A, Basri C, Kamso S, Manaf A, Pranoto A, et al. Pedoman nasional pengendalian tuberkulosis. Jakarta: Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan Kemenkes RI; Bab 3, Tatalaksana pasien tuberculosis; 2013. p. 32-7.
5. Nazir A, Imam SF, Shabbir I, Saleem S. Adverse drug reaction of first line anti-tuberculosis drugs used in DOTS implemented setting in Lahore. Pakistan J Med Res 2015;54:101-4.
6. Lu X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One 2013;8:e65037.
7. Chantaphakul H, Cheungpasitporn W, Ruxrungtham K, Klaesongkram J. Adverse reaction to anti-tuberculosis drugs. J Allergy Clin Immunol 2010;125:AB154.
8. Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, et al. Design of the anti-tuberculosis drugs induced adverse reactions in China national tuberculosis prevention and control scheme study (ADACS). BMC Public Health 2010;10:1-9.
9. Delgado KC, Montag AR, Bravo SG, Segovia EV, Montoya AS, Garbin AN. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One 2011;6:e27610.
10. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3:37-49.
11. Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011;6:e21836.
12. Kenward H, Pelligand L, Bataille KS, Elliot J. Nausea: current knowledge of mechanisms, measurement and clinical impact. Veterinary J 2015;203:36-43.
13. Rian S. Pengaruh efek samping obat anti tuberkulosis terhadap kejadian default di rumah sakit islam pondok kopi jakarta timur januari 2008–Mei 2010 [Thesis]. Fakultas Kesehatan Masyarakat Universitas Indonesia; 2010. p. 7-31.
14. Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC Public Health 2011;11:696.
15. Gallardo CR, Comas DR, Rodriguez AV, Figuls MR, Parker LA, Cayla J, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Systematic Rev 2016;17:CD009913.
16. Pan X, Wang L, Grundemann D, Sweet DH. Interaction of ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug interactions during antituberculosis therapy. Antimicrob Agents Chemother 2013;57:5053-9.